High Prevalence of Chronic GH Deficiency and Approval and Launch of New Products to Augment Growth of Human Growth Hormone Market
Human
growth hormone is a protein hormone that promotes cellular growth,
reproduction, and cell differentiation in humans and many other animals. It is
therefore vital in human growth. It helps maintain the normal functioning of
the reproductive organs, controls body temperature, orchestrates cell division,
orchestrates the development of the nervous system, governs blood pressure, and
helps maintain the skin's elasticity. It also has effects on other body tissues
such as the eyes, liver, pancreas, kidneys, stomach, and adrenal glands.
Market Dynamics
High prevalence of
chronic GH deficiency is expected to boost growth of the global
human growth hormone market. For instance, according to the study, “Prevalence
of growth hormone deficiency in middle-age adults recovering from stroke”,
published in the journal Brain Injury, in October 2019, GHD was diagnosed in
54% of patients, with 32% falling into the severe category.
Moreover, approval and
launch of new products is also expected to aid in growth of the market. For instance, in September 2020, The US Food
and Drug Administration approved somapacitan (Sogroya, Novo Nordisk) for the
replacement of endogenous growth hormone in adults with growth hormone
deficiency.
However, skepticism
about over-the-counter human growth hormone claims is expected to hinder growth
of the global human growth hormone market. Use of growth hormone therapy in
children also increases the risk of cardiovascular diseases in adulthood. Such
side effects are also expected to limit the market growth.
Among
regions, Asia Pacific is expected to witness significant growth in the global
human growth hormone market, owing to
approval
and launch of new products in the region. For
instance, in August 2020, I-Mab, a clinical stage biopharmaceutical company, announced
that the China National Medical Products Administration has accepted its
pivotal trial application for eftansomatropin (also known as TJ101) as a weekly
treatment for growth hormone deficiency in pediatric patients.
Competitive Analysis
Major
players operating in the global human growth hormone market include, Pfizer
Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, OPKO
Health Inc., Novo Nordisk, Sandoz
International GmbH, Ferring Holding SA, and Ipsen.
Major
players operating in the global human growth hormone market are focused on
R&D to expand their product portfolio. For instance, in October
2019, OPKO Health Inc. announced that the global Phase 3 trial evaluating
somatrogon dosed once-weekly in pre-pubertal children with growth hormone
deficiency (GHD) met its primary endpoint of non-inferiority to daily
GENOTROPIN (somatropin) for injection, as measured by annual height velocity at
12 months.
Comments
Post a Comment